Senior Scientist, Degrader Antibody Conjugate Cellular Pharmacology

BioSpace

Brisbane (CA)

On-site

USD 162,000 - 174,000

Full time

8 days ago
Application generator

Stand out for this role — generate a tailored resume and cover letter in about a minute.

Get past ATS filters

Job summary

Nurix Therapeutics seeks a Senior Scientist to define and drive in vitro screening and pharmacological characterization for Degrader Antibody Conjugates (DACs). You will design cellular assays, lead cross‑functional collaboration, and advance candidates from primary screening to candidate selection with minimal supervision.

The role requires expertise in ADC/DAC fields, mammalian cell culture, and automated workflows.

Qualifications

  • PhD in Biochemistry, Pharmacology, Biology, etc. with 4+ years post‑grad experience, or MS with 8+ years industry experience.
  • Experience designing and setting up in vitro pharmacology studies and screening cascades; ADC/DAC experience preferred.
  • Leadership in a matrixed, cross‑functional environment with influence and alignment across teams.

Responsibilities

  • Shape integrated characterization plans for DACs and biologics across in vitro pharmacology.
  • Design, build, and drive the in vitro pharmacology and screening framework for DACs.
  • Lead design and execution of pharmacology studies to assess activity and mechanism of action.

Skills

In vitro pharmacology
ADC/DAC expertise
Matrixed leadership
Cell-based assays
Mammalian cell culture
Automation workflows
Data interpretation
Leadership communication

Education

PhD in Biochemistry/ Biology
MS with industry experience

Tools

Automation systems

Job description

Senior Scientist - Degrader Antibody Conjugate Cellular

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix's dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.

We are seeking an accomplished scientific leader who will define and drive our in vitro screening and pharmacological characterization capability for Degrader Antibody Conjugates (DACs). Our DAC platform pairs antibody-based targeting with our degrader expertise to direct protein degradation to specific cell types, and this scientist will own the in vitro strategy defining how candidate molecules move through the screening cascade - from primary screening - through mechanistic pharmacological characterization of drug candidates.

This is a hands-on leadership role for someone who has built deep expertise in the ADC and/or DAC field and wants to apply that experience in designing and running in vitro pharmacology studies into a highly collaborative discovery organization, while operating with a high degree of scientific independence. The scientist will independently design, execute, and analyze cellular assays that characterize DAC activity, and will partner closely with discovery biology, conjugation chemistry, analytical biochemistry, DMPK, and automation to advance candidates from early screening through development candidate selection. Success depends as much on scientific vision, influence, and communication as on technical depth: the ideal candidate is self-driven, resourceful, and organized — a strong strategic thinker, an effective and compelling presenter, and a proven leader who can align and drive teams in a matrixed setting without relying on direct authority.

Responsibilities
  • Bring rich knowledge of the preclinical drug discovery workflow for ADCs/DACs to shape integrated characterization plans, connect in vitro pharmacology to in vivo and translational strategy, and anticipate the data packages needed for candidate progression.
  • Design, build, and drive the in vitro pharmacology and screening framework for DACs and biologics, from primary screening through mechanistic and quantitative characterization.
  • Serve as a key scientific decision-driver for DAC in vitro pharmacology, providing sound judgment on assay strategy, data interpretation, and go/no-go recommendations.
  • Lead and influence a matrixed, cross-functional organization, partnering with discovery biology, conjugation chemistry, analytical biochemistry, DMPK, and chemistry automation to translate strategy into execution and to advance multiple programs in parallel.
  • Lead the design and execution of pharmacology studies, working closely with team members, to assess the biological activity and mechanism of action of lead molecules and drug candidates.
  • Develop and perform cell-based assays to characterize DAC and biologic activity, including antigen binding, target engagement, and targeted protein degradation, using cutting-edge technologies and automated workflows.
  • Cultivate and maintain mammalian cell lines (experience manipulating cell surface antigens and engineering reporter lines used to characterize DACs is preferred).
  • Stay current with the latest scientific literature and industry developments in the fields of ADCs, DACs, biologics, and targeted protein degradation.
  • Mentor and develop scientists, in a matrixed environment, to build team capabilities and ensure compliance to best practices.
  • Communicate and champion scientific findings and strategy through clear, compelling presentations to project teams and senior leadership; author study reports and technical documentation, and drive scientific discussions that shape project direction.
Qualifications
  • Ph.D. in a relevant scientific field (Biochemistry, Pharmacology, Biology, etc.) with 4 or more years of relevant post‑graduate industry or academic research experience, or MS with 8 or more years of relevant industry experience.
  • Demonstrated experience designing and setting up in vitro pharmacology studies and screening cascades; prior experience building screening/assay cascades in the ADC or DAC field is strongly preferred.
  • Demonstrated leadership in a matrixed, cross-functional environment, with the ability to influence, align, and drive teams and programs.
  • Excellent communication and presentation skills, with a track record of clearly conveying complex science and recommendations to project teams and senior leadership.
  • Hands-on experience with mammalian cell culture and the ability to independently execute, analyze, and report results of quantitative cellular assays relevant to conjugate characterization (e.g., luminescence-based degradation, viability, or internalization assays).
  • Experience with mechanistic assays that dissect DAC activity, such as antibody binding and intracellular drug release, is highly desired.
  • Familiarity with automation equipment (e.g., liquid handlers) and automated workflows.
  • Strong analytical and problem-solving skills, with sound judgment in evaluating and interpreting experimental data.
  • Demonstrated ability to manage priorities and advance multiple projects simultaneously in a matrixed, cross-functional environment.
Salary

$161,900 - $173,900

Location

Brisbane, CA (Onsite role)

Nurix Culture and Values
  • Strong team orientation; highly collaborative
  • Solutions and results-oriented focus
  • Hands-on approach; resourceful and open to diverse points of view
Get your free, confidential resume review.

or drag and drop your file here.

Similar jobs

Similar jobs worth comparing

Senior Scientist -Degrader Antibody Conjugate Cellular Pharmacology
Senior Scientist -Degrader Antibody Conjugate Cellular Pharmacology

Initial Therapeutics, Inc. • Brisbane (CA)

On-site
USD 180,000 - 240,000
Senior Scientist -Degrader Antibody Conjugate Cellular Pharmacology
Senior Scientist -Degrader Antibody Conjugate Cellular Pharmacology

Nurix Therapeutics • Brisbane (CA)

On-site
USD 127,000 - 143,000
Senior Scientist, Degrader Antibody Conjugate Cellular Pharmacology
Senior Scientist, Degrader Antibody Conjugate Cellular Pharmacology

NURIX • San Francisco (CA)

On-site
USD 180,000 - 250,000
Scientist I, Bioanalytical – Drug Antibody Conjugates (DACs)
Scientist I, Bioanalytical – Drug Antibody Conjugates (DACs)

Initial Therapeutics, Inc. • Brisbane (CA)

On-site
USD 124,000 - 143,000
Scientist I, Bioanalytical – Drug Antibody Conjugates (DACs)
Scientist I, Bioanalytical – Drug Antibody Conjugates (DACs)

BioSpace • Brisbane (CA)

On-site
USD 124,000 - 143,000
Scientist II, Degrader Antibody Conjugate Characterization
Scientist II, Degrader Antibody Conjugate Characterization

NURIX • South San Francisco (CA)

On-site
USD 133,000 - 148,000
Scientist, Bioanalytical – Drug Antibody Conjugates (DACs) Brisbane, California
Scientist, Bioanalytical – Drug Antibody Conjugates (DACs) Brisbane, California

Nurix, Inc. • California (MO)

On-site
USD 130,000 - 170,000
Scientist II, Degrader Antibody Conjugate Characterization Brisbane, CA
Scientist II, Degrader Antibody Conjugate Characterization Brisbane, CA

Nurix, Inc. • California (MO)

On-site
USD 140,000 - 161,000
Scientist II, Degrader Antibody Conjugate Characterization
Scientist II, Degrader Antibody Conjugate Characterization

Initial Therapeutics, Inc. • Brisbane (CA)

On-site
USD 140,000 - 161,000
Scientist II, Degrader Antibody Conjugate Characterization
Scientist II, Degrader Antibody Conjugate Characterization

BioSpace • Brisbane (CA)

On-site
USD 140,000 - 161,000